A new study in Frontiers in Pharmacology has demonstrated for the first time that the transcription factor MEF2D inhibits ferroptosis by upregulating long-chain ACSL3, therefore facilitating sorafenib resistance in HCC. The gene discussed is ACSL3; the disease is hepatocellular carcinoma.